InvestorsHub Logo
Followers 21
Posts 590
Boards Moderated 0
Alias Born 11/12/2009

Re: oc631 post# 601

Saturday, 09/13/2014 4:52:29 PM

Saturday, September 13, 2014 4:52:29 PM

Post# of 2961

The two heavyweights (GILD/ABBV) are quite evenly matched



Thanks for the laughs :))

ABBV/ ENTA are LIGHTWEIGHTS in HCV and their drug candidates will fall by the wayside ... the nukes, NS5As and PIs from GILD, MRK/IDIX and ACHN are far more valuable than anything ABBV/ ENTA have to offer!!!!

ACHN will be bought out following 3422 POC ... as I said, it's similar to sovaldi and they have multiple legal opinions on FTO & patentability ...

We will know soon enough about 3422 ... meanwhile you can content yourself with your holdings in ENTA ...

I should add that 2684 is a far better PI than any PI from ABBV/ ENTA

Large pharma continues to acquire weak (or worthless) HCV assets at premium prices so anything's possible.



A presumptuous assertion!! ... so you think you know more than the people at these pharma who make M&A decisions? ... does the acquisition of VRUS by GILD for 7977 (sovaldi) fall into the category you mention? ... there were plenty of ignorant second guessers who said it was foolish for GILD to pay $11 billion for VRUS ... we know how that worked out!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News